Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Por Dumez, Herlinde, Gallardo, Enrique, Culine, Stephane, Galceran, Joan Carles, Schöffski, Patrick, Droz, Jean P., Extremera, Sonia, Szyldergemajn, Sergio, Fléchon, Aude
Publicado em 2009

Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma

Por Schöffski, Patrick, Guillem, Vincente, Garcia, Margarita, Rivera, Fernando, Tabernero, Josep, Cullell, Martin, Lopez-Martin, Jose Antonio, Pollard, Patricia, Dumez, Herlinde, del Muro, Xavier Garcia, Paz-Ares, Luis
Publicado em 2009

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Por Awada, Ahmad, Dumez, Herlinde, Aftimos, Philippe G., Costermans, Jo, Bartholomeus, Sylvie, Forceville, Kathleen, Berghmans, Thierry, Meeus, Marie-Anne, Cescutti, Jessica, Munzert, Gerd, Pilz, Korinna, Liu, Dan, Schöffski, Patrick
Publicado no Invest New Drugs (2015)

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

Por Mateo, Joaquin, Olmos, David, Dumez, Herlinde, Poondru, Srinivasu, Samberg, Nancy L, Barr, Sharon, Van Tornout, Jan M, Jie, Fei, Sandhu, Shahneen, Tan, Daniel S, Moreno, Victor, LoRusso, Patricia M, Kaye, Stan B, Schöffski, Patrick
Publicado no Br J Cancer (2016)

(18)F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study

Por Emonds, Kimy M, Koole, Michel, Casteels, Cindy, Van den Bergh, Laura, Bormans, Guy M, Claus, Filip, De Wever, Liesbeth, Lerut, Evelyne, Van Poppel, Hendrik, Joniau, Steven, Dumez, Herlinde, Haustermans, Karin, Mortelmans, Luc, Goffin, Karolien, Van Laere, Koen, Deroose, Christophe M, Mottaghy, Felix M
Publicado em 2013